
MYmAb Biologics Recognized as a BioNexus Status Company
MYmAb Biologics Recognized as a BioNexus Status Company March 2025 – We are thrilled to announce that MYmAb…
MYmAb Biologics Recognized as a BioNexus Status Company March 2025 – We are thrilled to announce that MYmAb…
Tissue Microarrays (TMAs): Applications in Tumour Biology Tissue Microarrays (TMAs) have transformed cancer research, offering an innovative platform…
Tissue Microarray for Clinical Research Tissue microarray (TMA) is a cutting-edge, high-throughput technology revolutionizing the analysis of molecular…
MYmAb Biologics’ Founder, Dr. Jia-Xin Chua, Featured on Asia Business Outlook At MYmAb Biologics, we’re proud to share…
An Overview of the Different Types of Human Tissue Microarrays (TMAs) Recent advancements in cancer research have been…
Cancer Statistics in Southeast Asian Countries: Gender, Types, and More Cancer is one of the most pressing public…
Cancer Statistics in South, East & South-Eastern Asian Countries: Gender, Types, and More Cancer remains one of the…
How Tissue Microarrays (TMA) Contribute to Translational Research: Bridging the Gap Between Lab and Clinic What is Translational…
Digital Pathology – An Advanced Way to Preserve Your Research Outcome In today’s rapidly evolving world of medical…
MYmAb Biologics Receives RM 1.3 Million GVPD Grant for Tissue Microarray Development August 2024: We are excited to…
Immunohistochemical Staining Breast Cancer: An Overview Breast cancer, a prevalent concern among women worldwide, requires precise diagnostic methods…
What is Tissue Microarray? Tissue microarray (TMA) is a groundbreaking innovation in the field of pathology, designed to…